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Here, we evaluate the diagnostic and prognostic role of liquid-based cytology (LBC) in
different body lesions, including thyroid, lung, effusions and malignant breast lesions. LBC
has gained consensus after being applied to both non-gynecologic and fine-needle aspiration
cytology. Although some remain sceptical regarding the diagnostic efficacy of LBC, mainly
when used alone, in recent years, good results have been obtained as long as it showed a
high diagnostic accuracy. Here, we discuss the additional possibility of storing material for the
application of ancillary techniques (immunocytochemistry–molecular analysis) with several
diagnostic and prognostic advantages, which may pave the way for the challenging
evaluation of both monitoring responses to treatment and resistance to targeted therapies in
thyroid, lung, breast carcinoma or malignant effusions. Furthermore, it provides the use of
several molecular spots as specific targets for personalized therapy.
KEYWORDS: effusions . immunocytochemistry . liquid-based cytology . malignancy . molecular analysis
. nodular lesions . targeted therapies
Fine-needle aspiration cytology (FNAC) is the
first and worldwide diagnostic procedure
applied in the field of both palpable and deep
body lesions [1,2]. It has found a widespread
application because of its simplicity, safety and
cost–effectiveness leading to a correct diagnosis
concerning the nature of the lesions in >70%
and to a correct clinical approach in > 90% of
patients regardless of the site [1]. To some
extent, conventional cytology (CC) has been the
cornerstone method for many years even though
it copes with some important drawbacks repre-
sented by: the unpredictable rate of inadequate
samples and the diagnostic difficulties in defin-
ing the overall efficacy and specificity in some
diagnostic samples. Based on the figures of inad-
equacy and false-negative results, CC was
openly discussed and criticized in some specific
contexts including mainly cervical cytology,
breast, lung and thyroid lesions [3–6].
The introduction in 1996 of liquid-based
cytology (LBC) has gained enthusiasm as a
new technique for collection and preparation
of cytological specimens, first in cervical cytol-
ogy and then with the application on FNAC
with reliable and feasible results [1,7,8]. The two
most common US FDA-approved methods for
processing the cytological samples use an
alcohol-based fixative solution. In the first
method (ThinPrep5000TM, Hologic Co.,
Marlborough, MA, USA), the cells are
aspirated from a methanol-based solution
(CytolytTM), then filtered and transferred onto
a positively charged slide with a gentle positive
pressure. This method was characterized by a
collection of cells into a methanol-based pre-
servative solution then processed with a fully
or semi-automated device reducing the back-
ground interference from blood, inflammatory,
debris and cells overlapping.
In the second method, the cells are collected
in an ethanol-based solution (CytoRichTM),
centrifuged twice then slowly sedimentated
onto a poly-L-lysinated slide and eventually
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stained with a specific hematoxylin–eosin stain (SurePathTM,
TriPath Imaging, Burlington, NC, USA). The final result for
both methods is one slide for each lesion where all cells are
concentrated in a thin layer on the central area of the slide
measuring 20 mm2 for ThinPrep and 13 mm2 for SurePath.
Apart from their specific characteristics, we did not find any
significant difference in the cytological evaluation, which may
invalidate a correct interpretation of the lesion. Furthermore,
LBC introduction improved the diagnostic efficacy in several
cytological steps through procedure, standardization of method,
sample quality improvement, screening support, speedup and
quality control [7,8]. The growing interest in the new cytological
preparation raised the well-known conflicting opinions and
controversial data regarding the efficacy of LBC even if several
aspects in terms of cost–effectiveness, time-sparing and first and
foremost in the easy application of ancillary techniques such as
immunocytochemistry (ICC) and molecular biology must be
underlined [1,7–11]. We aim to exploit some of its important
advantages that are related to the assessment method, including
the reduction of inadequate samples, better fixation of cells, the
clean and purified background that enhances the nuclear details
of lesions even though a training is advisable for a complete
knowledge of all the main differences with conventional
cytological preparations.
Nevertheless, one of the additional major advantages of LBC
is the feasible use of the residual material for the extraction of
high-quality DNA/RNA even after a long period of stor-
age [7–11]. Inasmuch as cancer therapy is becoming more and
more targeted, LBC may represent a promising and feasible
method for approaching the knowledge of genetic changes in
cancer and their tailored treatment in a presurgical phase [9].
Thyroid cytology
Thyroid morphology
The cytological evaluation of thyroid lesions represents the first
and widely accepted screening method for the diagnosis of thy-
roid nodules with high sensibility and diagnostic accuracy,
which is counterparted by lower specificity [1,2]. Taking into
account the distribution of thyroid lesions, approximately
65–70% are benign, 5–10% are malignant while the remaining
25–30% represent a ‘gray zone’ in which different follicular
entities are diagnostically included [1,2,12–15]. The attempt of
deciding on the extent of surgery in a case of indeterminate
cytology remains a vexing question and a difficult challenge. In
fact, this latter category includes several subcategories (follicular
neoplasm [FN], suspicious for malignancy and atypical cells of
undetermined significance) that are not always accurately
defined, bearing a different risk of malignancy and different
surgical treatments with a quite high rate of unnecessary thyroi-
dectomises and an expected 20–30% rate of malignancies [11–15].
The evaluation of morphology alone could create some misun-
derstanding and pitfalls so that several authors encouraged the
use of ancillary techniques as sensitive markers in providing
estimated risk of malignancy [1,2,8–11,16–19]. To some extent, the
application of LBC provided the possibility to easily carry out
these techniques with material stored in the preservative
solution.
Ancillary techniques on thyroid cytology
Literature data show that several papers have been set out on
the use of ICC in thyroid FNAC without any regard to the
cytological method used [1,2,8–11,20]. In fact, some data support a
feasible ICC application on cell blocks yielding both 100% sen-
sitivity and specificity, as well as Cochand-Priolett et al. reck-
oned 100% sensitivity, 85.2% specificity and 100% negative
predictive value with anti-mesothelioma antibody 1
(HBME-1) and cytokeratin 19 [11,20,21]. Eventually, utilization
of an ICC panel may be the best choice as highlighted by some
authors and by Rossi et al. stating that HBME-1 and Galectin-3
were able to discriminate between low and high risk of malig-
nancy in FNs with 92% overall diagnostic accuracy in concor-
dant positive ICC cases [22]. Rarely does the detection of
positive ICC prove to be more than a suggestion of malignancy
while the high specificity of molecular detections, classified as
‘rule-out’ or ‘rule-in’ tests, is a strong indicator of cancer,
enabling physicians to accurately balance risk and reward in
selecting a treatment and follow-up [2,17,19,23–25]. The challenging
advances in molecular genetics of thyroid cancer have been
applied for identifying new diagnostic markers of malignancy
also on FNAC [2,17,19,23,24]. The diagnostic role of FNAC in rec-
ognizing malignancies is mostly represented by the identification
of papillary thyroid carcinoma (PTC) and the assumption that
BRAF, RET/PTC or RAS mutations are found in >70% of PTC
also associated with a more aggressive tumor behavior [26–28]. In
many reports, BRAF mutations, mainly involved in the activa-
tion of MAPK pathway, have been correlated with extrathyroidal
extension, advanced tumor stage at presentation and lymph
node or distant metastases with the final impairment of the
function of the sodium iodide symporter and of other genes
metabolizing iodide. All these processes are involved in the
unfavorable prognosis of these patients [27–31]. Specifically, the
association of BRAFV600E mutation with a poorer outcome on
FNAC assumes a significant diagnostic role and provides valu-
able prognostic information for a preoperative risk stratification
of thyroid lesions [27–30]. In this perspective, the role of BRAF
mutations on FNAC has been assessed by several studies in
which both DNA and RNA analyses were applied on CC or
LBC as recently reported by Chang et al. [8–10,12]. Hence,
Rossi et al. referred that the detection of BRAFV600E mutation
in the suspicious for malignancy has a 100% histological corre-
lation with a diagnosis of thyroid carcinoma (p = 0.0353),
lymph-node metastases (p < 0.0001), extracapsular invasion
(p = 0.03) and multifocality (p = 0.0003), envisaging a more
aggressive surgical treatment [8]. From a diagnostic point of
view, a comparison between ICC results and gene mutations in
the FN category assessed that an ICC panel is more likely to
achieve a diagnosis than BRAF analysis, especially due to the
great percentage of follicular variant of PTC (FVPC) with high
wild-type BRAF prevalence [19]. We reported 87.5% wild-type
BRAF in the FNs diagnosed as FVPC on histology whilst
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Nikiforov et al. and Ohori et al. reported a higher incidence of
BRAFV600E mutation ranging from 25 to 33% FNs [8,19,26].
Hence, many authors agree that BRAFV600E mutation has
been highly associated with PTC (FIGURE 1) and more often with
the aggressive variants (e.g., tall cell and columnar variants) as
well as some rarer and uncommon BRAF mutations are more
frequent in FVPCs and linked with less aggressive behavior
and/or encapsulated variants [31,32]. Although these rarer muta-
tions induce partial kinase activity and alter amino acids which
are essential for catalysis leading to an oncogenic BRAF activa-
tion [27], the need for prospective trials may extend the role of
predictive significance of BRAF mutations to patients with low
risk PTC or its variants as well as it has assessed the role in
advanced metastatic radioactive iodine-refractory disease where
patients may benefit from BRAFV600E-targeted kinases. Since
the evaluation of MAPK or other DNA pathways did not pro-
vide complete and exhaustive achievements, we reasoned that
thyroid lesions, especially FN category, might be studied with
miRNAs. These miRNAs are small endogenous, non-coding
RNAs that are negative regulators of gene expression with a
role in regulating cells proliferation, differentiation and sur-
vival [33–35]. Thyroid tumors have been associated with deregu-
lation of different miRNA profiles including miR-221,
222 and 146b which seem to be mostly upregulated in classical
PTCs, while the new promising miR-375 resulted in PTC,
FVPC and also in medullary thyroid carcinoma [33–35]. Specifi-
cally, miR-375 upregulated expression may be a negative regu-
lator of the expression of YAP1 (a growth inhibitor) and
SLC16a2 (a transporter of thyroid hormone) and it may induce
an aggressive behavior in terms of residual disease, lymph node
and distant metastases and mortality. Especially in medullary
carcinoma, which may benefit from the new frontiers of spe-
cific targeted therapies, miR-375 may accompany or even sup-
plant conventional clinic–pathologic risk factors and this may
open, as well as in breast carcinoma, to a prognostic and pre-
dictive significance in personalized tailored therapies based on
the molecular yields easily carried out on LBC.
The evidence of patients harboring BRAF-mutated carcino-
mas, either resistant to radioiodine de novo or becoming refrac-
tory to radioiodine, supports the growing role of LBC in the
management and monitoring of mutations for both therapeutic
responses and resistance to therapy. The latter, which is
explained by the association between BRAFV600E mutation and
the loss of radioiodine avidity, may be sought and detected in
the cytological phase and consequentially treated with MEK
inhibitors. Few clinical studies carried out in vitro with geneti-
cally engineered mice demonstrated that inhibitors of MAPK
signaling pathway may restore iodine uptake in BRAFV600E
iodine-resistant carcinomas [35].
Lung cytology
Lung morphology
Lung cancer represents the first worldwide leading cause of can-
cer death and one of the major public health concerns [36].
Despite the increasing number of new cases per year and the
need for screening programs, this malignant entity is more fre-
quently discovered for symptoms or chest radiographs performed
for other intents in many cases recognized as a locally advanced
or metastatic disease with only a few of them eligible for surgical
resection [36]. In the complex diagnostic workup, cytology
(including exfoliative respiratory cytology) is often underutilized
and underestimated as the first tool to obtain diagnostic material.
This mainly happens due to the location of the nodule and the
number of possible pitfalls and false positive/negative diagnoses
without a conclusive cytological report [36]. Despite this evidence,
the rediscovered role of cytology in patients with metastatic or
locally advanced tumors has been enhanced by the increased use
and excellent results of minimally invasive diagnostic procedures
used for diagnosis and staging of lung cancer, such as endobron-
chial ultrasound-guided biopsy [37,38]. Its essential role was proven
not only in achieving the correct diagnosis but mostly in leading
to the application of molecular testing regardless of the cytologi-
cal method [36].
Lung molecular insights
In the last two decades, increasing knowledge of the molecular
pathogenesis of lung cancers has maximized the role of targeted
therapies, especially, but not exclusively, for unresectable
malignancies (FIGURE 2) [38–41]. Taking together these data, the
discovery of the functional activation of EGFR as well as ana-
plastic lymphoma kinase (ALK) gene rearrangement seems to
support both prognostic and predictive benefit for therapeutic
response with some targeted agents such as tyrosine kinase
inhibitors (TKIs) [38,39]. This represents a new challenge since,
until few years ago, the central role of cytology had been
mainly restricted to the morphological differentiation between
small cell and non-small cell lung carcinomas without any pos-
sible further diagnostic or prognostic implication [40–45].
According to the latest recommendations of the international
Figure 1. Details of the morphological features of cells
obtained from a ‘positive for malignancy-PTC’ case on
liquid-based cytology (40).
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Association for the Study of Lung Cancer, the American Tho-
racic Society and the European Respiratory Society, all lung
adenocarcinomas should be analyzed for EGFR and/or KRAS
mutations [37]. Not only did review articles, original studies and
guidelines appraise the feasible role of CC, but also they
reported the equal efficacy of LBC when compared with CC
and histological samples in providing outstanding material for
gene mutational assays, essentially in the EGFR and KRAS
genes [40–42]. Moreover, recently Malapelle et al. demonstrated
that conventional smears showed higher DNA yields and were
more frequently cell-rich than the LBC slides even though the
difference in adequacy and in mutant EGFR rate between the
two samples types did not reach a statistical significance [43,44].
Hence, the application of LBC does not affect DNA or RNA
quality and molecular testing as confirmed by some studies
involving both conventional and LBC techniques on FNAC
and exfoliative samples [43–45]. The latter aspect seems to
involve some limitations in the presence of an exfoliative respi-
ratory cytological sample mainly due to the high proportion of
benign epithelial cells, which may lead to inconclusive results.
The precious quality of cytological preparations needs to be
validated by large cytological series, which are often quite scant
apart from the one from Billah et al. including a series of
209 cytological samples supporting and validating the use of
cytological samples as a reliable source of EGFR and KRAS
molecular detection in lung cancer [40].
It is known worldwide that EGFR mutations are detected in
10–40% of lung tumors and highly correlated with a selected
group of patients, including women, never smokers and adeno-
carcinoma histology. Furthermore, 70–80% of patients demon-
strated a better clinical outcome and disease-free survival rate
when treated with first-line EGFR inhibitors, including gefitinib
or erlotinib [36–39]. The majority of EGFR mutations (about 90%)
are either short in-frame deletions in exon 19 or point mutations
in exon 21 (p.L858R) caused by the alteration of ATP/inhibitor
binding site, stabilizing the binding of the drugs and potentiating
their inhibitory effects. On the other hand, other less common
mutations (p.G719A in exon 18 and p.L861Q in exon 21) also
increase susceptibility to TKIs [37–39,45,46]. On balance, we have to
deal with the fact that not all activating mutations confer sensitiv-
ity to TKIs. In fact, some in vitro studies have demonstrated that
mostly exon 20 EGFR mutations render the receptor less sensitive
to the TKIs supported by the evidence that insertions/deletions
and the substitution of p.T790M in exon 20 induce resistance to
TKIs [37–39,45,46]. From this standpoint, the screening for all EGFR
mutations can be applied on cytology not only to select specific
treatments but also to detect primary or acquired resistance to
TKIs. Our previous paper on cytological lung cancer samples ana-
lyzed for molecular testing (including common and rare EGFR
mutations) led to our assessment that a mutation is detectable in
small cytological samples with also low yield of genomic DNA so
that the size and yield of the specimen are not necessarily limiting
factors for mutational analysis [45]. Although the gold standard
input level of DNA amount is validated in our everyday practice
with 20% of neoplastic cells, the rate and amount of tumor cells
higher than 20%, without any further subquantitative evaluation,
did not influence our mutation detection [45]. Our second success-
ful challenge in EGFR mutations detection on cytological as well
as on histological samples was the detailed identification of rarer
mutations, both primary and acquired, in exons 18 and 20 that
can maximize the adoption of alternative and more ‘personalized’
tailored therapies in a very early phase of patient diagnosis. Even-
tually, the sensitivity of molecular application on FNAC material
may vary a lot using different methods that seek the need to prop-
erly validate the molecular procedure in every laboratory.
Cytological samples, including LBC, represent an effective alter-
native method with high DNA and RNA quality also in the close
future perspective of obtaining outstanding cellular results for
genome sequencing such as the application of next generation
sequencing (NGS) also in the ample field of lung cancer [46].
Since then, the introduction of NGS has been only carried out
with CC (both FNAC and exfoliative cytology) and based on
scraping or laser micro-dissection as long as mutational profiles
may be affected by the amount of specific DNA and the propor-
tion of malignant cells versus possible contaminations with non-
tumor cells. New series with NGS carried out on LBC samples
need to be confirmed. Moreover, a recent paper by Buttita et al.
demonstrated EGFR mutations, corresponding to those detected
in histological samples, in 42% of the samples without cytopatho-
logical evidence of neoplastic cells highlighting the superior sensi-
tivity of the NGS diagnostic approach and the possibility to use
somatic mutations of frequently mutated genes in lung tumors
(i.e., p53, KRAS and EGFR) for early diagnosis in fluid samples
(sputum, broncho-alveolar lavage and pleural effusion) [47].
Effusions cytology
Serous effusions
Malignant cells found in serous effusions are significantly
related to poor survival rates and, consequently, this finding is
generally accepted as a hallmark of dismal prognosis [48].
Figure 2. Details of the morphological features of lung
adenocarcinoma (liquid-based cytology, 40).
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Despite the increasing and growing interest in use of all the
modern laboratorial resources in serous effusions examination,
the principal approach is still characterized by the cytological
evaluation of these effusions (including pleural, pericardial and
peritoneal), which has not been completely assessed in all its
potentialities in these past years [49–51]. Some recent studies
reported that one-fifth of body’s serous membrane effusions
per year are malignant with approximately 50% as metastatic
adenocarcinomas (FIGURE 3) followed by pulmonary large cell car-
cinomas and lymphomas/leukemia (about 15% each) [48–51].
The challenging implications of the presence of malignant
cells in effusions highlight that an accurate cytological evalua-
tion is the critical and mainstream diagnostic tool, mainly
encouraged by its simplicity, safety and cost–effectiveness in
reducing all the possible consequences and complications of a
more aggressive biopsy procedure that often may even fall short
of adequate diagnostic material [48–52]. In some cases, these
serous effusions are the only available material for diagnosis, so
that the recognition of maligant cells as well as the discrimina-
tion with reactive mesothelial cells need the identification of
specific cellular findings regardless of the cytological methods
which include conventional smears, cytospin, cell blocks and
LBC [48,52–56].
Ancillary techniques on effusions
In this perspective, ancillary techniques, such as fluorescence
in situ hybridization, chromogenic in situ hybridization, telo-
merase assays, comparative genomic hybridization and
microarray-based comparative genomic hybridization, are car-
ried out in order to ascertain an accurate diagnosis. Although
different groups report good results with each of these techni-
ques, we extensively use LBC as the leading method for the
morphological evaluation of the cytological findings in effu-
sions. Besides, an article by Hoda evaluated all the known
literature for the morphological aspects of LBC in non-
gynecological cytology as well as the accuracy of both Thin
Prep and SurePath in the interpretations of effusions in align-
ment with the data from Ylagan [51,57]. Keeping these evidences
in mind, we recently analyzed our 13-year experience with the
application of LBC effusion preparation underscoring the pros
and cons of this method. In detail, we reported 72 ovarian
metastatic carcinomas in which WT-1 was not specific in rul-
ing out the correct diagnosis, while CA125 combined with
other markers (including keratin 7 and Calretinin) showed a
good specificity in the discrimination with mesotheliomas.
Moreover, the hotspot evidence that only 49 negative effusions
were diagnosed as a malignant biopsy result (1.5%) underlined
the high negative predictive value of LBC effusions [58].
A recent article published by Shah et al. evaluated the use of
effusion fluid for NGS-based, multigene mutation profiling for
personalized treatment [59]. Another recent paper by
Davidson et al. identified vimentin and Zeb1 as markers of
poor chemoresponse in metastatic serous ovarian carcinoma
effusions and suggested NCAM as a potential prognostic
marker of metastatic disease [60].
Additionally LBC offered the strong diagnostic aid of the
accurate application of ancillary techniques (both molecular
testing and ICC) on effusion cytology ended up in a lucky
application of these techniques for diagnostic, therapeutic and
prognostic especially when LBC is adopted [48–51]. The micro-
environment setting of malignant effusion is complex and com-
posed of a plethora of different elements that comprise, among
others, the cells and molecules from blood and lymphatic circu-
lation, cells and structural components of serous membrane,
and the malignant cells with their varied phenotypes and
related molecular products [52]. Because serous effusions can be
invaded by tumors originating in different anatomic regions,
cytopathological investigation of these samples can offer differ-
ent levels of morphological interpretation that encompass the
identification of an unknown primary site of a malignancy, his-
togenetic discrimination of malignant cells (if certain malignant
cells represent sarcomas, carcinomas or lymphomas), if the
atypical cellular morphology represents malignant or benign
alterations or if the malignant cells are metastatic or resi-
dents [53,54]. Despite lack of an unquestionable marker of malig-
nancy until now, there are a number of monoclonal and
polyclonal antibodies that can compose different immunocyto-
chemical panels currently used to enhance the performance of
cytological investigation. These panels are designed to recognize
hormone products of malignant cells secretion, such as calcito-
nin, thyroglobulin, estrogen (ER), progesterone (PR) and
others; or products that identify the structural components of
the normal cells that originated certain malignancies, such as
vimentin, keratins, melanin and others [55,56]. The possibilities
are immense, and presently it is possible to address antibodies
against a number of molecules that are involved with cellular
metabolism, tyrosine kinase receptors, growth factors, interleu-
kins and other players present in malignant effusions [60,61].
Not surprisingly, most of these markers are targetable for
Figure 3. Details of the morphological features of perito-
neal malignant effusion from a gastric carcinoma (liquid-
based cytology, 40).
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therapeutic proposals, and ongoing efforts are now focused to
improve not only diagnoses and prognoses, but cancer therapy
as well [60].
Special attention has been dedicated to the advanced-stage
ovarian carcinoma metastasized to serous effusions that is recog-
nized as an aggressive malignancy with poor survival rates, fre-
quently. The heat shock protein 90 (HSP90), which shows an
anti-apoptotic activity, was recently tested by both Elstrand et al.
and Shoshan’s groups evaluating the role of HSP90 in 265 effu-
sions from women with advanced-stage ovarian carcinoma [61–64].
They found that HSP90 nuclear expression was significantly
higher in samples of women post-chemotherapy when compared
to effusions from women pre-chemotherapy effusions
(p = 0.005), and significantly related to previous treatment with
both Platinol (p = 0.024) and paclitaxel (p = 0.007). Cyto-
plasmic HSP90 expression, on the contrary, was significantly
higher in effusions from women with complete compared with
incomplete/no response after second-line chemotherapy
(p = 0.016). However, no association was found between
HSP90 expression and other clinicopathologic parameters or sur-
vival. The authors concluded that HSP90 does not provide prog-
nostic data in patients with advanced ovarian carcinoma
effusions. Conversely, they proposed that HSP90 is a potential
therapeutic target in this patient group, because HSP90 may ben-
efit from treatment with HSP90 inhibitors to potentiate the
effectiveness of Platinol and paclitaxel in patients with recurrent
advanced ovarian carcinoma effusions through a possible interac-
tion with glucose metabolism [61–64]. Antiangiogenic therapy is
also a new paradigm for cancer patients with malignant serous
effusions. The old premise that starving tumor is a potential and
reliable option for cancer treatment has nowadays increased
options of different strategies that merit careful attention [61].
Yano et al., for example, elegantly evaluated this model of ther-
apy. They studied malignant pleural mesothelioma, a tumor that
is constantly refractory to the conventional chemotherapy and
radiotherapy [65]. As angiogenesis plays a critical role in mesothe-
lioma progression, the authors investigated the molecular patho-
genesis and evaluated the efficacy of vascular targeting therapy in
mesothelioma. They found that selective VEGF inhibitors were
effective to treat mesotheliomas that highly express VEGF. In
addition, they found that multiple kinase inhibitors (E7080),
which potentially inhibit various angiogenic receptors, suppressed
mesothelioma progression and prolonged survival in both high-
VEGF-producing and low-VEGF-producing mesothelioma
models. This is a remarkable finding because a number of
different strategies with other molecules that modulate cancer
progressions and survival present in malignant effusion microen-
vironment can be evaluated with very promising results [66].
There are many mechanisms of resistance to anti-VEGF therapy
recognized at the moment; various malignancies are able to
bypass the angiogenic obstruction [65]. However, there are prom-
ising improvements combining molecular players involved in
metabolic response and hypoxia with anti-angiogenic armamen-
tarium. The recent years witnessed increasing evidence associat-
ing the hypoxic and metabolic responses related to the tumor
adaptation against anti-angiogenic therapy. The transcription fac-
tor hypoxia-inducible factors are recognized as the principal play-
ers that induce metabolic and phenotypic changes, including
increased ability to facilitate invasion and metastasis [65]. The
combination of anti-angiogenic agents with inhibitors of tumor
hypoxic and metabolic adaptation is believed to be of great
promise, as anticipated [67]. This combinatination has been inno-
vatively reported for more than a decadebefore the cancer cell-
enhanced glycolysis, measured by glucose transporter-1 investiga-
tion, has proved to be essential for the survival adaptation of
tumor cells in effusions [67]. These findings have been later
revised by Liao et al., who postulated that increased expressions
of glucose transporter-1 and carbonic anhydrase IX combination
are indubitable parameter of malignant effusion [66]. Another way
to escape anti-angiogenic blockage was studied by Fuang and col-
leagues who reported the effect of Endostar, a recombinant
human endostatin expressed and purified in Escherichia coli, com-
bined with an angiopoietin-2 specific inhibitor, L1-10, on mouse
model with injected lung carcinoma cells in malignant pleural
effusion. They demonstrated a significant synergistic effect on
the formation of malignant pleural effusion and tumor growth;
in addition, the authors also evinced that Endostar combined
with L1-10 plays a role in the reduction of pleural inflammation
and inhibition of tumoral angiogenesis and pleural hyper-perme-
ability. The authors hypothesized that Endostar combined with
L1-10 could complementarily act by reducing the local VEGF
and local IL-6 and downregulating VEGF expression in pleural
tumors [68]. The examples discussed so far are sufficiently robust
to reveal the huge potential of serous effusion samples as a fasci-
nating biological tool for therapeutic proposals.
Breast cytology
FNAC still has a role in the assessment of breast lesions, espe-
cially in the context of clinical and radiological benign nodules,
symptomatic breast lumps and breast malignancies (local recur-
rences, metastasis, advance breast tumors in patients with poor
clinical conditions and assessment of lymph node status) [69].
Nonetheless, the success of FNAC is highly dependent on the
adequate collection and preparation of the cytological
smears [70,71]. When there are no trained practitioners to ade-
quately handle FNAs, the LBC technique may overcome prob-
lems related to ill-preserved specimens and poorly prepared
smears [72]. Indeed, air-drying and spreading artefacts are signif-
icantly reduced in LBC preparations [72,73].
In general, LBC provides better cellular preservation, less cell
overlapping and elimination of obscuring background elements
when compared to conventional smears [72,74,71]. On the other
hand, alterations in architecture and cellular morphology have
been described in FNAC specimens processed with LBC and
prior training in evaluation and interpretation of LBC speci-
mens is necessary to avoid potential diagnostic pitfalls [72,73,75].
Architectural changes have been reported in LBC prepara-
tions, including fragmentation of cellular aggregates that results
in cellular dissociation and smaller clusters [75]. One study
showed that 3D arrangements were more pronounced in breast
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lesions prepared as LBC specimens [73]. These architectural fea-
tures – small clusters, loss of cohesion, 3D configuration – are
potential sources for an erroneous diagnosis of malignancy.
Usually, cell morphology is better preserved in LBC specimens
with an enhancement of the nuclear detail, including the pres-
ence of well-defined nucleoli [73,75]. The myoepithelial cells
(bipolar cells) are commonly decreased in number and some of
them show an intact cytoplasm resembling fibroblasts or epi-
thelial cells [72].
LBC specimens often demonstrate a clean background due
to the elimination of obscuring elements such as blood, inflam-
matory cells and cellular debris [73–75]. However, an
‘informative’ background may also be eliminated, including the
loss of mucous, stromal fragments and fat tissue.
As a result of the architectural and cell changes described
above, some types of breast lesions prepared as LBC specimens
present different cytological features in comparison to those
found on conventional smears. In particular, the diagnosis of
fibroadenoma seems to be the most problematic: small cell
aggregates, enhanced cellular dyshesion coupled with prominent
nucleoli, decreased numbers of myoepithelial cells and loss of
stromal fragments are commonly found in LBC specimens and
may potentially result in an erroneous diagnosis of malig-
nancy [73–75]. Conventional smears and LBC preparations have
comparable performance in detecting breast carcinomas [73,74].
Some studies observed a reduced size of neoplastic epithelial
clusters in comparison to conventional smears [73–75]. Nuclear
features such as hyperchromasia, less coarse chromatin and
more prominent nucleoli were described by Ryu et al. in breast
carcinomas processed by the LBC technique (FIGURE 4) [73].
Conventional smears and LBC present similar diagnostic
performance for non-gynecological cytological specimens. One
study that compared matched conventional smears and LBC
preparations found 100% sensitivity for detection of malig-
nancy in breast specimens for both methods [75]. However, in
this study, the LBC technique showed a lower specificity rate
(74%) for classifying benign breast lesions in comparison to
conventional smears (93%) [75]. Another study that evaluated
the LBC technique in 352 cases of benign and malignant breast
aspirates found a few number of false-negative and false-
positive cases, resulting in high sensitivity (97.7%) and specific-
ity (98%) rates [75]. As previously discussed, prior training in
interpreting LBC specimens is very important to achieve high
diagnostic accuracy. In fact, one study showed a decrease in
false-negative rate (from 12 to 4%) coupled with an improve-
ment in sensitivity (from 86 to 94%) after LBC training [73].
Ancillary techniques on breast cytology
Specific cell receptors such as the hormonal receptors (ER and
PR receptors) and the HER-2 are therapeutic targets in breast
cancer. Therefore, the investigation of these receptors is manda-
tory in cases of invasive breast carcinoma. Hormone-positive
tumors, for example, are usually responsive to hormonal thera-
pies and have a better outcome [76]. When evaluated by the
immunohistochemistry method, around 80% and 60–70% of
invasive breast carcinomas are positive for ER and PR, respec-
tively. The evaluation of hormonal receptors expression by
immunohistochemistry can be performed in a variety of
cytological preparations (conventional smears, LBC specimens
and cell blocks) and the results are similar to those found in
formalin-fixed and paraffin-embedded (FFPE) tissue speci-
mens [77]. Leung and Bedard [78], for example, showed an over-
all accuracy of 97 and 89% for detection of ER and PR,
respectively, in breast aspirates processed by the LBC tech-
nique. An important advantage of LBC versus conventional
smears is the preservation of hormonal receptors antigenicity
for long periods of time. One study showed that immunostain-
ing for ER and PR was preserved on LBC slides stored at
room temperature for up to 56 days [78].
Approximately 15% of the patients with invasive breast can-
cer present amplification of the HER-2 gene. Specific therapies
against the HER-2 protein are recommended for those patients
whose tumors are HER-2 positive, including protein expression
scored 3+ by immunohistochemistry or gene amplification
determined by in situ hybridization (ISH) techniques such as
fluorescence ISH, chromogenic ISH or silver ISH [76]. Well-
defined recommendations for the assessment of HER-2 status
in breast cancer were established by the American Society of
Clinical Oncology and the College of American Pathologists
on FFPE breast material such as those obtained by core needle
biopsies or excisional specimens [79]. Indeed, the results of
HER2 immunohistochemistry assessment in cytological speci-
mens are variable in the literature. Some studies showed a
poor-to-moderate agreement of HER2 testing between breast
aspirates processed by different cytological methods (conven-
tional smears, LBC specimens) and FFPE tissue samples [80].
However, the assessment of HER2 status in cell block prepara-
tions from breast aspirates seems to be reliable and highly con-
cordant rates were observed between these preparations and the
FFPE standard tissue sections in recent studies [81,82]. In
Figure 4. Details of the morphological features of breast
ductal carcinoma (liquid-based cytology, 40).
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contrast to immunohistochemistry, a good correlation between
cytological and tissue section specimens has been demonstrated
for the determination of HER2 status in breast cancer by ISH
techniques. High concordance rates of HER2 status were found
between LBC specimens and FFPE histological sections using
fluorescence ISH and chromogenic ISH [83] techniques.
A concordance rate of 96% between LBC specimens and histo-
logical material was achieved in a study that investigated the
role of the dual silver ISH technique for the evaluation of
HER2 status in a series of 47 invasive breast carcinomas [84].
We conclude that in spite of the peculiar cytological features
that require appropriate training to avoid interpretative errors,
LBC has similar diagnostic accuracy for the evaluation of breast
FNAC specimens compared with conventional smears. Some
advantages of LBC technique also have to be emphasized such
as the easier way to collect the samples (overcoming poor
cytological preparations) and the possibility for preserving mate-
rial for ancillary tests such as immunohistochemistry and ISH
methods. Therefore, LBC can be safely and routinely applied
not only for the diagnosis, but also for the prognostic and pre-
dictive evaluation of primary and metastatic breast cancer.
Expert commentary
Based on its high diagnostic accuracy, LBC may be used as a
valid alternative method to CC. Several papers underlined that
LBC adoption reduces the number of non-diagnostic (both
inadequate and artefactual) and indeterminate cases without
impairing the distinctive malignant features of lesions. The
storage of a variable amount of well-preserved cells allows for
the application of immunocytochemical and molecular
techniques that dramatically improve the efficacy of the mor-
phologic diagnosis in each of the body site analyzed here. This
assessment may promote continuous interest in the application
of all the ancillary techniques with results as reliable as those
obtained with small biopsies or surgical specimens.
Five-year view
The feasible results obtained with the application of LBC in
different body lesions demonstrate the outstanding role of this
method in achieving conclusive results with ancillary techni-
ques. Relevant molecular testing features overlap and overrun
those obtained with CC so that in future development, several
guidelines may take into account the central role of LBC as an
effective preparation for molecular testing and tailored thera-
pies. This may be highly recommended in deeply located neo-
plasms and locally advanced patients who may benefit from
any possible and available targeted therapies and longer survival
supported by the cytological findings. Additionally, the
‘nightmare’ of a resistance mutational assessment may be fore-
seen on cytological samples establishing that cytology is a viable
method for the use of molecular platforms and targeted NGS
as a simultaneous testing for multiple mutations in the era of
personalized targeted medicine.
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Key issues
. Liquid-based cytology offers several advantages in the management and diagnostic evaluation of different body lesions based on a
uniform, thin-layer distribution of cells.
. This technique introduces some cytomorphological features that are dissimilar from those of conventional cytology, including both
architectural and cellular findings.
. Some authors demonstrated a higher statistical significant improvement in sensitivity and diagnostic accuracy after a 6-month period of
training.
. Standardization in the method with uniform yields and homogenous cell distribution is one of the major strength attributed to this
method.
. Liquid-based cytology residual material may be used for the application of ancillary techniques, including immunocytochemistry,
molecular analysis and in situ hybridization with feasible and reliable results.
. The additional costs to the laboratory are counterbalanced by the decreased number of slides and the reduced slide surface.
. The application of molecular analysis with excellent results paves the way for the presurgical management of specific tailored therapies.
. Future research will provide great opportunities to analyze tumor genetics with a small quantity of cells and material as we have on
cytology. This may offer new insights for the resistances to some specific therapies.
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